Researchers at four University of California medical centers have begun recruiting for a phase 2 clinical trial to investigate the safety and efficacy of remdesivir for treating adults with COVID-19.
The NIH-sponsored trial will consist of a series of two-arm comparisons between different therapeutic agents and a placebo. New arms will be introduced as needed and will allow for early stoppage if any agents prove ineffective or unsafe.
The trial will begin with a small cohort of hospitalized patients diagnosed with COVID-19. It is projected to run until April 1, 2023 and will ultimately include about 440 participants.